TORONTO, ONTARIO -- (MARKET WIRE) -- October 23, 2006 -- OccuLogix, Inc. (NASDAQ: OCCX)(TSX: OC) today announced that the Company and Asahi Kasei Medical Co., Ltd. ("Asahi") of Japan have signed a distribution agreement covering the 2nd generation polysulfone Rheofilter™ ("Rheofilter™ SR") component of OccuLogix's RHEO® System for the treatment of the dry form of age-related macular degeneration ("Dry AMD").
